Excimer Laser Technology
EyeLight Innovations
Excimer Laser Technology
ELT technology used by all companies in the space was created and developed by EyeLight Innovation's founder Dr. Michael Berlin. This technology has been approved for use in Europe under CE mark for well over 10 years. With validated safety and efficacy in over 5,000 patients in European studies, ELT was still not readily adopted in the United States due to its implementation difficulty. We created a guidance system technology which solves this problem, making it possible for all ophthalmic surgeons to perform this MIGS procedure accurately. MIGS not only makes ELT widely adoptable, but also more accurate by implementing data in real-time.
​
Our plan is to make Endoscopic and Guided Excimer Laser Trabeculostomy the Gold Standard of glaucoma care in the U.S.
-
Guided ELT opens the pathway for adoption, allowing all cataract surgeons to perform the surgery.
-
More surgeons in the USA will be enabled to have access to the procedure.
-
4x more patients will benefit from this more accurate procedure (45 million within 10 years, as opposed to 10 million with standard, less accurate, ELT and stent-based MIGS).
-
Guided ELT is based on 40+ unique issued and pending patents.
-
$5 billion market for Guided ELT with few barriers to entry:
-
Remuneration CPT codes for ELT and Endo 2D ELT are already established. 8
-
Remuneration CPT codes for 3D ELT may enable even greater valuation for reimbursement.
-
-
We envision additional easily-adaptable applications for this unique patented system.
Leadership Team
A Message From The Founder
I have been a glaucoma specialist for over 40 years. When I began treating patients, our treatment options were inefficient and ineffective. For decades I searched for alternative and permanent solutions. There were no such options. I wanted something better for my patients and when I later learned that I also have glaucoma, I knew I had to find a lasting, vision saving solution.
As a part of the scientific team which created what is now called “LASIK”, I applied this same technology to the treatment of glaucoma and created ELT. Fortunately, this concept worked. Over 7,000 glaucoma patients have been safely and successfully treated in Europe and I’m proof, myself. I underwent ELT in 2014. It works.
Invest in the Future of Sight
EyeLight Innovations is enabling some of the best and brightest minds in the world of ophthalmology, merging vision and technology. With an aggressive
18-month development model, we're aiming to disrupt an industry through innovation. Your support will enable the best alternative to preserving vision in patients with Glaucoma.
EyeLight Innovations
4705 Riva De Romanza St.
Las Vegas, NV 89135
(310) 855-1112
